Skip to main content
Premium Trial:

Request an Annual Quote

MRM Proteomics, Agilent Enter Comarketing Agreement for Quantitative Proteomics

NEW YORK – MRM Proteomics and Agilent Technologies said Thursday that they have entered a comarketing agreement for quantitative proteomics tools.

The partnership will cover Santa Clara, California-based Agilent's mass spectrometry products with Montreal-based MRM's kits for protein and metabolite quantitation.

MRM will develop assay kits specifically for Agilent's 6495 Triple Quad mass spec coupled to an Evosep One HPLC system. The company will also host in-person and virtual workshops on targeted quantitative proteomics workflows as well as the operation of the Evosep LC system.

"The new targeted proteomics workflows that have been developed through our collaboration with MRM Proteomics and Evosep will improve quantification of protein targets in clinical research and accelerate drug development in sample-limited environments," Jennifer Gushue, associate VP of mass spectrometry marketing at Agilent, said in a statement. "This collaboration highlights the capabilities of our 6495 LC/MS Triple Quadrupole as a winning combination with Evosep and MRM proteomics for targeted proteomics and our commitment to driving answers for the toughest analytical challenges."

Financial and other terms of the agreement were not disclosed.

The Scan

Positive Framing of Genetic Studies Can Spark Mistrust Among Underrepresented Groups

Researchers in Human Genetics and Genomics Advances report that how researchers describe genomic studies may alienate potential participants.

Small Study of Gene Editing to Treat Sickle Cell Disease

In a Novartis-sponsored study in the New England Journal of Medicine, researchers found that a CRISPR-Cas9-based treatment targeting promoters of genes encoding fetal hemoglobin could reduce disease symptoms.

Gut Microbiome Changes Appear in Infants Before They Develop Eczema, Study Finds

Researchers report in mSystems that infants experienced an enrichment in Clostridium sensu stricto 1 and Finegoldia and a depletion of Bacteroides before developing eczema.

Acute Myeloid Leukemia Treatment Specificity Enhanced With Stem Cell Editing

A study in Nature suggests epitope editing in donor stem cells prior to bone marrow transplants can stave off toxicity when targeting acute myeloid leukemia with immunotherapy.